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Dear Editor,
I  read the very interesting report by Zriouil et al.1 Although I
understand  it was  not the aim of the study to evaluate specif-
ically  the vancomycin susceptibility of the isolates, I would
like  to make a comment regarding the laboratory methods of
choice  for this evaluation.
The  authors state that all isolates “were still susceptible to
vancomycin” and that vancomycin was  “100% active against
the  two groups of Staphylococcus aureus”. It is important to
remember  that vancomycin disk-diffusion test is not sufﬁ-
cient  to rule out vancomycin intermediate resistance in S.
aureus,  and a minimum inhibitory concentration (MIC) test
should  be performed routinely in clinical isolates.2 One impor-
tant  obstacle is the heterogeneity of the results of different
vancomycin MIC  methods, including microdilution and Etest.3
Nevertheless, these tests provide results with critical clinical
implications.
There  is also discussion in the literature about the possi-
ble  association between increased MICs within the susceptible
range  and mortality in S. aureus infections.4 In this case MIC
results  should be used only as an additional parameter for
therapeutic decisions, being the clinical response the primary
one.
Of  note, elevated vancomycin MIC  has been also associ-
ated  with mortality in patients with methicillin-susceptible S.
aureus infections treated with oxacillin. Phenotypic alterations
that  usually occur in vancomycin-intermediate Staphylococ-
cus  aureus, including but not limited to cell wall thickening,
may  prevent other antimicrobial agents, as beta-lactams and
daptomycin,  to fully exert their mechanism of action.5
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